GlassScriptPhysician profile
Joshua A Grosshandler
NPI 1023320389
$478,666.10
in general payments reported to CMS, 2019-2025
41 companies · $158K in 2025
The $158K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $25K · 2021: $24K · 2022: $32K · 2023: $76K · 2024: $114K · 2025: $158K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $285K · Travel and Lodging: $23K · Consulting Fee: $18K · Food and Beverage: $17K · Honoraria: $4,273 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $284,995.50 |
| Travel and Lodging | $22,650.05 |
| Consulting Fee | $18,130.00 |
| Food and Beverage | $17,407.81 |
| Honoraria | $4,272.58 |
| Education | $129.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $186,895.18 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Ucb, INC. | $128,912.55 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $50,176.60 | 2020-2025 | Otezla, Otezla |
| Celgene Corporation | $31,807.85 | 2019 | |
| Vyne Pharmaceuticals INC. | $22,228.62 | 2020-2021 | |
| Almirall LLC | $18,017.80 | 2019-2025 | Klisyri, Seysara |
| Arcutis Biotherapeutics, INC. | $10,175.55 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $6,343.51 | 2021-2025 | Sotyktu |
| Organon LLC | $6,171.92 | 2025 | Vtama |
| Epi Health, LLC | $3,651.78 | 2019-2022 | |
| Abbvie INC. | $3,133.24 | 2019-2025 | |
| Journey Medical Corporation | $1,643.03 | 2022-2025 | |
| Janssen Biotech, INC. | $1,459.76 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $1,113.22 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $752.95 | 2019-2025 | Dupixent, Libtayo |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Grosshandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.